More than 30% of patients treated with life-changing therapeutics do not respond, or relapse, even with continued treatment. Enosi Life Sciences’ founders are building upon their Lasker Award-winning research to address and conquer these issues.
Enosi’s founders are developing breakthrough biologics that will bring drugs with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. This will be the next generation of autoimmune, cancer, and acute inflammation therapies that induce disease regression and prevent relapse while reducing patient side effects.
Enosi focuses on creating therapeutics that attack diseased cells, but not healthy cells. This results in fewer toxic effects on the patient. For instance, treatment of autoimmune disease with the current leading therapies results in an increased frequency of unusual infections, sometimes leading to death and even the occurrence of additional autoimmune disease in the same patient. In the case of cancer therapy, toxic chemotherapy is still the most common. Feldmann and Shepard aim to create new types of therapies that will be more effective and less toxic.